Logo

Chinese Herbal Medicine Firm’s Shares Surge 58,000% Despite No Revenue

Regencell Bioscience, a Hong Kong herbal medicine firm focusing on ADHD and autism treatments, saw its stock surge 58,000% despite never turning a profit. CEO Yat-Gai Au’s stake is now worth $25.6 billion. The company is self-funded and still in R&D, but analysts warn this spike may not be sustainable amid regulatory shifts and investor enthusiasm in alternative medicine.

Chinese Herbal Medicine Firm’s Shares Surge 58,000% Despite No Revenue

Unprecedented Stock Surge for Hong Kong-Based Herbal Medicine Company

A small Chinese herbal medicine manufacturer, Regencell Bioscience Holding Ltd., has taken the investment world by storm with an astonishing 58,000% surge in its share price, despite having no revenue to date. This explosive growth has propelled CEO Yat-Gai Au's stake, who owns 86% of the company, to a staggering value of $25.6 billion, eclipsing some of the biggest names on the global billionaire lists.

The Company at a Glance

Regencell Bioscience, headquartered in Hong Kong, specializes in traditional herbal treatments targeting neurodevelopmental disorders such as ADHD and autism spectrum disorder. While the company remains in the research and development stage, it has yet to generate profits and recently reported a loss of $4.4 million for the fiscal year ending June 30, 2024.

Remarkably, the business is largely self-financed by Yat-Gai Au, who has invested over $9 million out of his own pocket. According to company statements, both Regencell and its affiliated foundation are passion projects for Au, who remains committed to advancing their mission based on personal conviction.

Background and Challenges

Founded in 2014, Regencell markets and licenses traditional remedies developed by Au’s father, Sik-Kee Au, a former electronics engineer and security alarm business owner. However, the family's medical practices have faced scrutiny; Sik-Kee Au was found guilty of professional misconduct in 2021 by Hong Kong authorities related to overprescribing medications.

Adding to its challenges, the company currently lacks a chief medical officer following a resignation in 2022, underscoring its developmental stage and risks involved.

What’s Fueling the Stock Frenzy?

The dramatic surge in Regencell’s valuation appears to be driven by rising interest in alternative medicine in the United States alongside regulatory shifts encouraging such therapies. However, market analysts caution that this meteoric rise may be unsustainable, bearing resemblance to prior speculative bubbles within niche health-related stocks that ended in sharp declines.

Investors should exercise care amid the current enthusiasm, as the firm's fundamentals are yet to match its skyrocketing market price.

Elon Musk's Drug Use and Political Role Spark Controversy and Concern
Elon Musk's Drug Use and Political Role Spark Controversy and Concern

During 2024-2025, Elon Musk's drug use reportedly escalated significantly alongside his active support for Donald Trump’s campaign. His substance consumption, including ketamine and psychedelics, allegedly affected his behavior and health, causing alarm among associates. Musk’s political engagement extended beyond donations to prominent campaign involvement and a government transition role, where concerns about his conduct emerged. Concurrently, his complex personal life involving multiple children and legal disputes added to the controversy. Ultimately, Musk resigned from his political position, reflecting the challenges of balancing business, politics, and personal issues.

Elon Musk’s Drug Use Intensified While Advising Former President Trump
Elon Musk’s Drug Use Intensified While Advising Former President Trump

Elon Musk regularly consumed drugs including ketamine, ecstasy, and psychedelic mushrooms during his advisory tenure with former President Trump. His use reportedly increased significantly, leading to health concerns such as bladder issues. Holding a unique government status exempted him from normal federal drug restrictions. Questions remain about the impact of his substance use on his official duties and security clearances. Musk recently resigned after unusual conduct.

Elon Musk Faces Scrutiny Over Alleged Drug Use During Government Role
Elon Musk Faces Scrutiny Over Alleged Drug Use During Government Role

Elon Musk is under renewed scrutiny following reports of frequent ketamine and other drug use during his 130-day leadership of the Department of Government Efficiency in the Trump administration. Allegations include intake of ecstasy, psychedelic mushrooms, and numerous daily pills. Despite musk’s denials and claims of medical use, insiders suggest heavier consumption. His time in office was marked by erratic behavior and aggressive cost-cutting, causing widespread disruption. Musk continues political involvement, pledging substantial support for upcoming elections.

India's Dairy Sector Focuses on Sustainability and Support for Smallholders
India's Dairy Sector Focuses on Sustainability and Support for Smallholders

Celebrated on June 1, World Milk Day spotlights sustainability and climate resilience challenges in dairy. India, accounting for nearly 25% of global milk production, supports over 80 million farmers and contributes significantly to GDP. Despite rising costs and disease risks, the sector seeks targeted aid for smallholders, embracing low-carbon strategies and breed conservation to sustain growth and nutrition.

Trump Urges Apple to Manufacture iPhones in the US, Threatens Tariffs
Trump Urges Apple to Manufacture iPhones in the US, Threatens Tariffs

President Trump is urging Apple to manufacture its iPhones in the United States, threatening a 25% tariff on products made overseas, including in India. This push follows a conversation with Apple CEO Tim Cook and broadens to encompass all smartphone manufacturers. Industry experts warn that relocating production to the U.S. could dramatically increase costs for consumers. The debate surrounding tariffs continues as the White House remains unclear about their implementation.

India's Export Growth: Capitalizing on US Tariffs from Trump Era
India's Export Growth: Capitalizing on US Tariffs from Trump Era

Indian companies are experiencing robust export growth, leveraging competitive advantages from US tariffs imposed during the Trump era. Leaders from top firms report increased inquiries and capacity expansions, particularly in electronics and textiles. The prospects of a bilateral trade agreement further bolster optimism, even amidst challenges related to manufacturing costs and potential tariff changes.

Sridhar Vembu Discusses His Mother's Impact on His Career Choices
Sridhar Vembu Discusses His Mother's Impact on His Career Choices

Sridhar Vembu, founder of Zoho, shared a touching tweet about his mother's questioning of his AI work and travel commitments, revealing a common generational gap in understanding tech roles. His humorous exchange highlights the pressures many individuals in technology face from their parents regarding work-life balance. Users resonated with this theme, sharing their own experiences with similar parental expectations. Vembu's recent career transition adds context to this relatable discussion.

European Companies Reduce Investments in China Amid Economic Slowdown
European Companies Reduce Investments in China Amid Economic Slowdown

European companies are scaling back investments and cutting costs in China amid a slowing economy and heightened market competition, according to the 2025 Business Confidence Survey by the European Chamber of Commerce in China. Overcapacity in industries like electric vehicles and rising trade tensions with Europe and the U.S. are contributing to declining profits and lowered business confidence across nearly 500 surveyed firms.

Chinese Herbal Stock Surges Over 58,000% Despite Zero Revenue and Skepticism
Chinese Herbal Stock Surges Over 58,000% Despite Zero Revenue and Skepticism

Regencell Bioscience, a Hong Kong-based developer of traditional Chinese herbal remedies targeting childhood ADHD and autism, has seen its Nasdaq-listed shares surge over 58,000% in 2025 despite having no revenue or regulatory approvals. The spike followed a major stock split and reflects speculative trading amidst heightened interest in alternative medicines. Yet, limited clinical evidence and significant insider control invite caution among investors.

Air India Flight Returns to Delhi Amid Bali Volcanic Eruption Disruptions
Air India Flight Returns to Delhi Amid Bali Volcanic Eruption Disruptions

Volcanic activity at Mount Lewotobi Laki-Laki on Flores island disrupted air travel to Bali, prompting an Air India flight to return to Delhi. The eruption sent ash 10 km into the sky, causing widespread flight cancellations and village evacuations. Authorities warned of ongoing volcanic hazards but reported no immediate casualties.

UK Inflation Holds Steady at 3.4% in May, Supporting Interest Rate Pause
UK Inflation Holds Steady at 3.4% in May, Supporting Interest Rate Pause

UK inflation remained firm at 3.4% in May, with core inflation easing slightly but still elevated. The Bank of England is expected to hold interest rates steady amid ongoing inflationary pressures and economic uncertainty, particularly in light of rising energy prices fueled by Middle East tensions.